Sheaff Brock Investment Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $11.9M | Sell |
56,937
-3,835
| -6% | -$746K | 1.09% | 12 |
|
|
2024
Q4 | $10.8M | Sell |
60,772
-257
| -0.4% | -$47.3K | 0.94% | 17 |
|
|
2024
Q3 | $12.1M | Sell |
61,029
-1,541
| -2% | -$288K | 1.05% | 16 |
|
|
2024
Q2 | $10.7M | Sell |
62,570
-6,074
| -9% | -$1.01M | 1% | 17 |
|
|
2024
Q1 | $12.5M | Sell |
68,644
-5,970
| -8% | -$1.03M | 0.79% | 17 |
|
|
2023
Q4 | $11.6M | Sell |
74,614
-728
| -1% | -$106K | 0.89% | 17 |
|
|
2023
Q3 | $11.2M | Sell |
75,342
-1,119
| -1% | -$164K | 1.02% | 13 |
|
|
2023
Q2 | $10.3M | Sell |
76,461
-3,360
| -4% | -$493K | 0.87% | 19 |
|
|
2023
Q1 | $12.7M | Sell |
79,821
-4,541
| -5% | -$694K | 1.17% | 11 |
|
|
2022
Q4 | $13.6M | Buy |
84,362
+610
| +0.7% | +$93.5K | 1.34% | 9 |
|
|
2022
Q3 | $11.2M | Buy |
83,752
+3,616
| +5% | +$519K | 1.21% | 10 |
|
|
2022
Q2 | $12.3M | Sell |
80,136
-2,930
| -4% | -$448K | 1.02% | 10 |
|
|
2022
Q1 | $13.5M | Sell |
83,066
-9,384
| -10% | -$1.36M | 0.94% | 12 |
|
|
2021
Q4 | $12.5M | Sell |
92,450
-349
| -0.4% | -$41.2K | 0.84% | 13 |
|
|
2021
Q3 | $10M | Buy |
92,799
+10,452
| +13% | +$1.19M | 0.74% | 14 |
|
|
2021
Q2 | $9.28M | Buy |
82,347
+3,288
| +4% | +$370K | 0.67% | 19 |
|
|
2021
Q1 | $8.56M | Sell |
79,059
-7,799
| -9% | -$834K | 0.67% | 21 |
|
|
2020
Q4 | $9.31M | Sell |
86,858
-1,984
| -2% | -$191K | 0.78% | 14 |
|
|
2020
Q3 | $7.78M | Buy |
88,842
+137
| +0.2% | +$12.9K | 0.72% | 17 |
|
|
2020
Q2 | $8.71M | Sell |
88,705
-24,501
| -22% | -$2.16M | 0.86% | 12 |
|
|
2020
Q1 | $8.63M | Buy |
113,206
+1,790
| +2% | +$152K | 1.14% | 10 |
|
|
2019
Q4 | $9.87M | Buy |
111,416
+3,731
| +3% | +$310K | 0.96% | 13 |
|
|
2019
Q3 | $8.15M | Buy |
107,685
+438
| +0.4% | +$30K | 0.88% | 19 |
|
|
2019
Q2 | $7.8M | Buy |
107,247
+1,168
| +1% | +$91.8K | 0.84% | 16 |
|
|
2019
Q1 | $8.55M | Sell |
106,079
-871
| -0.8% | -$71.3K | 1.04% | 15 |
|
|
2018
Q4 | $9.86M | Sell |
106,950
-1,829
| -2% | -$161K | 1.55% | 11 |
|
|
2018
Q3 | $10.3M | Sell |
108,779
-1,208
| -1% | -$115K | 0.97% | 13 |
|
|
2018
Q2 | $10.2M | Buy |
109,987
+12,616
| +13% | +$1.23M | 1% | 11 |
|
|
2018
Q1 | $9.22M | Sell |
97,371
-8,729
| -8% | -$959K | 0.95% | 15 |
|
|
2017
Q4 | $10.3M | Sell |
106,100
-13,509
| -11% | -$1.27M | 1.33% | 12 |
|
|
2017
Q3 | $10.6M | Buy |
119,609
+11,306
| +10% | +$861K | 1.4% | 9 |
|
|
2017
Q2 | $7.85M | Buy |
108,303
+2,617
| +2% | +$176K | 1.03% | 16 |
|
|
2017
Q1 | $6.89M | Sell |
105,686
-4,558
| -4% | -$287K | 0.9% | 20 |
|
|
2016
Q4 | $6.9M | Sell |
110,244
-2,107
| -2% | -$129K | 0.87% | 23 |
|
|
2016
Q3 | $7.09M | Sell |
112,351
-4,401
| -4% | -$285K | 0.95% | 21 |
|
|
2016
Q2 | $7.23M | Buy |
116,752
+78,374
| +204% | +$4.78M | 0.92% | 21 |
|
|
2016
Q1 | $2.19M | Buy |
38,378
+3,351
| +10% | +$187K | 0.27% | 79 |
|
|
2015
Q4 | $2.08M | Buy |
+35,027
| New | +$2.02M | 0.24% | 104 |
|
Other funds holding ABBV
Sheaff Brock Investment Advisors's ABBV Position: Q1 2025 in Review
Sheaff Brock Investment Advisors reduced its AbbVie (ABBV) stake by 6.3% in Q1 2025, selling an estimated $746K and leaving 56,937 shares worth $11.9M. The position accounts for 1.09% of the portfolio, ranked #12.
Sheaff Brock Investment Advisors first reported a position in ABBV in Q4 2015 and has held it in 38 quarters since. The position peaked at $13.6M in Q4 2022. 3,819 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.
- Sheaff Brock Investment Advisors held 56,937 shares of AbbVie worth $11.9M as of Q1 2025.
- Sheaff Brock Investment Advisors sold 3,835 AbbVie shares in Q1 2025, an estimated $746K.
- AbbVie made up 1.09% of Sheaff Brock Investment Advisors's portfolio in Q1 2025, its #12 holding.
- Sheaff Brock Investment Advisors first reported a position in AbbVie in Q4 2015 and has held it in 38 quarters since.
- Sheaff Brock Investment Advisors's AbbVie position peaked at $13.6M in Q4 2022.
- 3,819 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.
Based on Sheaff Brock Investment Advisors's 13F filing for Q1 2025, filed 7 May 2025.